Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Metastatic Urothelial Cancer × avelumab × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 8 Carcinoma, Transitional Cell 8 Carcinoma, Renal Cell 5 Carcinoma, Merkel Cell 5 Neoplasms 4 Stomach Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Neoplasm Metastasis 3 Melanoma 3 Carcinoma, Non-Small-Cell Lung 3 Uterine Cervical Neoplasms 2 Urethral Neoplasms 2 Ureteral Neoplasms 2 Triple Negative Breast Neoplasms 2 Small Cell Lung Carcinoma 2 Skin Neoplasms 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 Turcot syndrome 1 Thymoma 1 Sarcoma 1 Prostatic Neoplasms 1 Peritoneal Neoplasms 1 Penile Squamous Cell Carcinoma (PSCC) 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Ovarian Neoplasms 1 Osteosarcoma 1 Motor Activity 1 Microsatellite Instability 1 Metastatic Urothelial Cancer 1

Interventions

zimberelimab 1 sacituzumab govitecan 1 pembrolizumab 1 enfortumab vedotin 1 avelumab 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡